Change of Adviser

RNS Number : 4449E

Renalytix AI PLC

06 November 2020

 

Renalytix AI plc

("RenalytixAI" or the "Company")

Change of adviser

NEW YORK, November 6, 2020  - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care ,  announces the appointment of Investec Bank plc as joint corporate broker, with immediate effect to work alongside its existing nominated adviser and joint broker, Stifel.

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker )		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally.  The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer.  Every day, 13 patients in the United States die while waiting for a kidney transplant.

*  https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com .

 

END

 

 

APPFSLFAIESSESF